LON:TRX - Tissue Regenix Group Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0.53
▼ -0.01 (-1.85%)

This chart shows the closing price for TRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tissue Regenix Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRX

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Tissue Regenix Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 0.53.

This chart shows the closing price for TRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Tissue Regenix Group. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/21/2017Jefferies Financial GroupReiterated RatingBuyGBX 39
6/5/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
12/7/2016Jefferies Financial GroupLower Price TargetBuyGBX 40 ➝ GBX 39
(Data available from 12/4/2016 forward)

News Sentiment Rating

-0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/4/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Tissue Regenix Group logo
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, Cardiac, and GBM-V divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material to reduce risk of injection; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for orthopaedics, trauma, and woundcare; DermaPure Non-Oriented Decellularised allograft dermal tissue for urogynaecology and general surgery; and SurgiPure XD, Decellularised xenograft dermal tissue for the repair of hernias and/or body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix for orthopaedics and spine; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedics, trauma, and spine; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure product; Matrix OI 100 DBM for spine and non-structural bone-grafting; Matrix OI Strips and Blocks, a cell containment scaffold; AmnioWorks for ophthalmology; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.
Read More

Today's Range

Now: GBX 0.53
Low: 0.51
High: 0.55

50 Day Range

MA: GBX 0.61
Low: 0.53
High: 0.67

52 Week Range

Now: GBX 0.53
Low: 0.40
High: 0.93

Volume

16,049,104 shs

Average Volume

27,738,250 shs

Market Capitalization

£37.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Tissue Regenix Group?

The following Wall Street sell-side analysts have issued stock ratings on Tissue Regenix Group in the last twelve months:
View the latest analyst ratings for TRX.

What is the current price target for Tissue Regenix Group?

0 Wall Street analysts have set twelve-month price targets for Tissue Regenix Group in the last year. has the lowest price target set, forecasting a price of £100,000 for Tissue Regenix Group in the next year.
View the latest price targets for TRX.

What is the current consensus analyst rating for Tissue Regenix Group?

Tissue Regenix Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TRX.

How do I contact Tissue Regenix Group's investor relations team?

Tissue Regenix Group's physical mailing address is Innovation Way, YORK, YO10 5NY, United Kingdom. The company's listed phone number is +44-1904-567609. The official website for Tissue Regenix Group is www.tissueregenix.com.